Pharmacogenomic Testing in Pain Management and Behavioral Health: A Pharmacist Perspective

• By: Ronnie Moore, PharmD Ludovick Youmbi, PharmD Angelo O’Neill, MSW Allure Specialty Pharmacy
• January 1st, 2020
• behavioral health, CYP2D6 enzyme, opioid use, pain management, personalized medicine, PGx testing, pharmacogenomics, treatment resistant depression
• 1774    0

Pain, in its many forms (e.g., nociceptive, neuropathic, inflammatory, etc.), affects upwards of 100 million people in the United States resulting in costs reaching $600 billion per year.1 Treatment of pain symptoms through the inappropriate prescribing and use of opioids has fueled an opioid abuse...